Amgen-Alexion deal rumors resurface, to the delight of investors and analysts

23rd August 2019 Uncategorised 0

Amgen may be on the verge of acquiring Alexion for $200 per share, a Spanish news site reported Thursday. Analysts say the deal makes sense and would prop up Amgen’s top and bottom lines, which are under pressure from biosimilar competition to key drugs Neulasta and Sensipar.

More: Amgen-Alexion deal rumors resurface, to the delight of investors and analysts
Source: fierce